

7:45 AM	Attendee Sign-In	
8:00 AM	Welcome, Treaty Land Acknowledgment, Virtual Housekeeping	
<b>Plenary Session 1</b>		
8:05AM - 8:35AM	20	<p><b>CPSS Guidelines and Standards   Dr. Morris Markentin</b> At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> <li>•Review the 'College of Physicians and Surgeons of Saskatchewan Opioid Agonist Therapy Program Standards and Guidelines'.</li> <li>•Summarize the educational and mentorship requirements.</li> <li>•Describe program restrictions for initiation and maintenance prescribers and special circumstances including hospital and corrections prescribers.</li> </ul>
	10	Q & A
<b>Plenary Session 2</b>		
8:40AM - 9:10AM	20	<p><b>CRNS Practice Requirements for Nurse Practitioners to Prescribe Opioid Use Disorder (OUD) Medications   Sherry Joa</b> At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> <li>• Become familiar with the CRNS Policy for prescribing OUD medications (the form has SRNA)</li> </ul>
	10	Q & A
<b>Plenary Session 3</b>		
9:15AM - 10:00AM	35	<p><b>Patient Assessment and Suitability   Dr. Andrew Yang</b> At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> <li>•Demonstrate proper clinical assessment.</li> <li>•Discuss nuances of informed consent for patients living with opioid use disorder starting on opioid agonist therapy, including potential side effects.</li> <li>•Strategies for communication and collaboration with family physician and other allied health care professionals.</li> </ul>
	10	Q & A
<b>Break (10 minutes)</b>		
<b>Plenary Session 4</b>		
10:10AM - 11:10AM	45	<p><b>Opioid Agonist Therapy: Benefits   Dr. Larissa Kiesman</b> At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> <li>•Develop an organized approach to OAT</li> <li>•Compare and contrast buprenorphine / naloxone and methadone</li> <li>•Learn the different approaches to induction</li> <li>•Understand dosage adjustments for stabilization, missed doses, and tapering</li> <li>•Place OAT in the context of a Recovery Oriented System of Care</li> </ul>
	15	Q & A
<b>Plenary Session 5</b>		
11:15AM - 11:45PM	20	<p><b>Urine Drug Screen to Optimize Treatment   Dr. Morris Markentin</b> At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> <li>•Understand the benefits and limitations of urine drug screening.</li> <li>•Offer tips for reducing tampering &amp; false/inaccurate results.</li> <li>•Incorporate urine drug screening in practice.</li> </ul>
	10	Q & A
<b>LUNCH BREAK (40 mins)</b>		
<b>Plenary Session 6</b>		
12:25PM - 12:55PM	20	<p><b>Carries: Balancing Safety and Access   Dr. Erin Hamilton</b> At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> <li>•Describe how carries can be put into practice.</li> <li>•Review the provincial standards and guidelines</li> </ul>
	10	Q & A
<b>Plenary Session 7</b>		
1:00PM - 2:00PM	45	<p><b>Role of the Pharmacist in OAT   Matt Manz</b> At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> <li>•Discuss the role of trauma informed care in pharmacy practice.</li> <li>•Explain the medication coverage for opioid agonist therapy in Saskatchewan.</li> <li>•List how pharmacists can make opioid agonist therapy more accessible and feasible for patients.</li> <li>•Describe how pharmacists can monitor and support patients on opioid agonist therapy, including review of potential drug interactions.</li> <li>•Explain the importance of pharmacists' involvement during transitions in care .</li> <li>•List potential harm reduction strategies pharmacists can provide.</li> </ul>
	15	Q & A
<b>Break (10 minutes)</b>		
<b>Plenary Session 7</b>		
2:10PM - 2:40PM	20	<p><b>OAT in Pregnancy &amp; Breastfeeding   Dr. Morris Markentin</b> At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> <li>•Review substance use disorder and addiction in pregnancy.</li> <li>•Consider opioid agonist therapy dosing for pregnant and breastfeeding patients.</li> <li>•Describe strategies for supporting antepartum and post-partum patients.</li> </ul>
	10	Q & A
<b>Plenary Session 8</b>		
2:45PM - 3:15PM	20	<p><b>Early Days as an OAT Provider   Dr. Brendan Groat</b> At the end of this session learners will be able to:</p> <ul style="list-style-type: none"> <li>•Discuss cases from experts working in addictions medicine.</li> <li>•Present early day expectations for prescribers starting to work as an opioid agonist prescriber.</li> </ul>
	10	Q & A
3:15PM - 3:25PM	10	Complete Survey for Certificate & Closing Remarks